BRISBANE, Calif.--(BUSINESS WIRE)--āshibio, a privately held biotechnology company developing novel therapeutics for the treatment of bone and connective tissue disorders, exited stealth mode today ...
Skeletal conditions such as developmental dysplasia of the hip (DDH), osteoporosis, and osteoarthritis affect millions worldwide, often causing chronic pain and disability. These disorders stem from ...
A new study explores the potential of fibroblast growth factor receptor (FGFR) antagonists in restoring defective mandibular bone repair in mouse models of osteochondrodysplasia, a group of genetic ...
Gain-of-function mutations in fibroblast growth factor receptor (FGFR) genes are known to cause a range of skeletal disorders, such as craniosynostosis and chondrodysplasia, which severely affect ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results